Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viracta Therapeutics
Biotech
Cash-strapped Viracta ends phase 2 study of lead cancer drug
Cash-strapped Viracta Therapeutics is continuing to reduce its options in order to stay financially afloat.
James Waldron
Jan 2, 2025 7:41am
Viracta begins 2nd round of layoffs in 3 months
Nov 7, 2024 5:02am
Viracta axes staff to slim down for race to cancer finish line
Aug 14, 2024 8:09am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Maxwell Biosciences taps 3 leaders—Chutes & Ladders
Sep 23, 2022 9:30am
Urovant hires Astellas alum Robinson as CEO—Chutes & Ladders
Mar 27, 2020 9:30am
